Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

INCORVAIA, Lorena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.666
EU - Europa 2.453
AS - Asia 1.140
SA - Sud America 295
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 9.597
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.641
IT - Italia 1.008
SG - Singapore 555
DE - Germania 432
CN - Cina 360
FI - Finlandia 276
BR - Brasile 261
GB - Regno Unito 136
UA - Ucraina 135
IE - Irlanda 114
RU - Federazione Russa 63
SE - Svezia 50
NL - Olanda 42
RO - Romania 41
IN - India 40
BE - Belgio 33
PL - Polonia 29
AT - Austria 28
HK - Hong Kong 26
TR - Turchia 26
IQ - Iraq 21
IR - Iran 18
FR - Francia 16
CI - Costa d'Avorio 15
CA - Canada 14
BG - Bulgaria 11
MY - Malesia 11
KR - Corea 10
UZ - Uzbekistan 10
ES - Italia 9
JP - Giappone 9
EC - Ecuador 8
AR - Argentina 7
CH - Svizzera 7
EG - Egitto 7
BD - Bangladesh 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
MX - Messico 5
PK - Pakistan 5
VE - Venezuela 5
JM - Giamaica 4
LT - Lituania 4
NP - Nepal 4
PE - Perù 4
UY - Uruguay 4
AU - Australia 3
AZ - Azerbaigian 3
CY - Cipro 3
CZ - Repubblica Ceca 3
EU - Europa 3
GR - Grecia 3
KZ - Kazakistan 3
PH - Filippine 3
TW - Taiwan 3
VN - Vietnam 3
CL - Cile 2
DK - Danimarca 2
KE - Kenya 2
KG - Kirghizistan 2
MM - Myanmar 2
NO - Norvegia 2
PS - Palestinian Territory 2
PY - Paraguay 2
SA - Arabia Saudita 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZA - Sudafrica 2
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CO - Colombia 1
CR - Costa Rica 1
EE - Estonia 1
GT - Guatemala 1
ID - Indonesia 1
IL - Israele 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MD - Moldavia 1
ML - Mali 1
PT - Portogallo 1
TH - Thailandia 1
TN - Tunisia 1
Totale 9.597
Salva come PNG Salva come JPEG
Città #
Fairfield 826
Chandler 578
Ashburn 544
Woodbridge 424
Houston 412
Singapore 334
Wilmington 318
Seattle 304
Ann Arbor 278
Palermo 258
Cambridge 256
Medford 132
Dublin 108
Rome 106
Helsinki 95
Munich 94
Altamura 89
Des Moines 87
Princeton 87
New York 83
San Diego 75
Ludwigshafen am Rhein 72
Lawrence 71
Jacksonville 68
Milan 53
Nanjing 51
Santa Clara 49
Boardman 41
Kitzingen 37
Beijing 35
Bremen 34
Brussels 33
Dearborn 33
Los Angeles 33
Nuremberg 32
London 31
Jinan 28
Changsha 25
Tulsa 24
São Paulo 18
Council Bluffs 17
Lappeenranta 17
Shenyang 17
Abidjan 15
Falls Church 15
Aversa 14
Kumar 14
Nanchang 14
Pune 14
Guangzhou 13
Washington 13
Milazzo 12
Vienna 12
Volla 12
Phoenix 11
Tianjin 11
Turin 11
Chicago 10
Falkenstein 10
Hebei 10
Jiaxing 10
Ningbo 10
Redwood City 10
Tehran 10
Cagliari 9
Central 9
Columbus 9
Dallas 9
Frankfurt am Main 9
Izmir 9
Verona 9
Amsterdam 8
Erbil 8
Kilburn 8
Rio de Janeiro 8
Saint Petersburg 8
San Mateo 8
San Paolo di Civitate 8
Shanghai 8
Tappahannock 8
Hong Kong 7
Messina 7
Naples 7
Orange 7
Seongnam 7
Tashkent 7
Toronto 7
Belo Horizonte 6
Bologna 6
Cairo 6
Edinburgh 6
Mascalucia 6
Monza 6
Moscow 6
Norwalk 6
Sofia 6
Taiyuan 6
Zhengzhou 6
Auburn Hills 5
Baghdad 5
Totale 6.818
Salva come PNG Salva come JPEG
Nome #
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 207
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 206
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 204
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 200
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 198
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 192
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 191
Liquid Biopsy in Breast Cancer 190
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 177
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 172
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 167
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 162
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma 159
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 159
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 157
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 154
Serum follistatin in patients with prostate cancer metastatic to the bone 153
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 148
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 147
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 145
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 144
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 143
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 135
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 134
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 133
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 124
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 122
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 119
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 119
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 117
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 114
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 112
Liquid Biopsy in Gynecological Cancers 108
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 103
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 102
Liquid Biopsy in Gastrointestinal Stromal Tumor 102
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 102
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 101
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 100
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 99
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 98
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 97
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 95
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 94
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 93
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 92
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 91
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 86
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 84
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 83
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 83
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) 81
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 81
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 74
Recent advances in desmoid tumor therapy 74
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 71
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 71
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 70
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 68
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 68
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 68
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 66
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 65
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 64
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 63
Cancer of the Thyroid 62
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 61
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 60
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon 60
I tumori stromali gastrointestinali: dalla biologia alla clinica 59
null 59
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report 58
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review 58
Body mass index as a risk factor for toxicities in patients with advanced soft-tissue sarcoma treated with trabectedin 57
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 54
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women 53
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 51
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 48
S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens 48
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 47
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 47
null 47
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 47
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison 47
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 47
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 46
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography 45
Molecular tumor board 44
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 41
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 41
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 41
Current clinically validated applications of liquid biopsy 40
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? 39
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 39
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 38
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 38
Mapping the landscape of immunonutrition and cancer research: A comprehensive bibliometric analysis on behalf of NutriOnc Research Group 36
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 36
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 34
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 34
Totale 9.463
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.661
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.661
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020350 0 0 0 0 0 0 0 0 0 130 165 55
2020/20211.332 61 51 100 93 183 87 101 92 146 162 157 99
2021/20221.264 87 186 59 28 53 70 55 69 113 162 166 216
2022/20231.686 170 306 37 217 160 245 91 143 169 33 75 40
2023/20241.184 43 127 104 112 76 181 145 122 24 65 21 164
2024/20252.133 117 153 140 267 151 232 417 283 243 130 0 0
Totale 10.400